The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

MDS 2021 | Thrombocytopenia in low-risk MDS

Name: Thrombocytopenia in low-risk MDS
Uploaded: 2021-09-22T00:00:00Z
Duration: 5 min 9 s
Description: Valeria Santini, MD, University of Florence, Florence, Italy, discusses the incidence of thrombocytopenia in low-risk myelodysplastic syndromes (MDS), outlining strategies for management. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.

Valeria Santini • 22 Sep 2021

MDS 2021

Anemias Myelodysplastic Syndromes Azacitidine CC-486

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the incidence of thrombocytopenia in low-risk myelodysplastic syndromes (MDS), outlining strategies for management. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.